Skip navigation
Browsing by Author Antonarakis, E. S.
Showing results 1 to 2 of 2
| Preview | Issue Date | Title / Name | Author(s) |
| 8-Aug-2025 | Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer | Mehra, N.; Antonarakis, E. S.; Park, S. H.; Goh, J. C.; McDermott, R.; Gonzalez, N. S.; Fong, P. C.; Griel, R.; De Santis, M.; Yanez, P. E.; Huang, Y. H.; Begbie, S. D.; Rey, F.; Kramer, G.; Suzuki, H.; Saretsky, T. L.; Ghate, S. R.; Cui, Y.; Hosius, C.; Yu, E. Y.; Begbie, Stephen | |
| Feb-2025 | A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study). | Crumbaker, M.; Shekar, S.; Lawrence, M.G.; Goldstein, L. G.; Yam, A. O.; Downton, T.; Begbie, S.; Zielinski, R.; Fox, W.; Araiza, N.; Yousif, J.; Ratnayake, L.; Antonarakis, E. S.; Denmeade, S. R.; Joshua, A. M.; Begbie, Stephen; Fox, William | |
